JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

被引：0

作者：

Toshihiko Wakabayashi

Atsushi Natsume

Junki Mizusawa

Hiroshi Katayama

Haruhiko Fukuda

Minako Sumi

Ryo Nishikawa

Yoshitaka Narita

Yoshihiro Muragaki

Takashi Maruyama

Tamio Ito

Takaaki Beppu

Hideo Nakamura

Takamasa Kayama

Shinya Sato

Motoo Nagane

Kazuhiko Mishima

Yoko Nakasu

Kaoru Kurisu

Fumiyuki Yamasaki

Kazuhiko Sugiyama

Takanori Onishi

Yasuo Iwadate

Mizuhiko Terasaki

Hiroyuki Kobayashi

Akira Matsumura

Eiichi Ishikawa

Hikaru Sasaki

Akitake Mukasa

Takayuki Matsuo

Hirofumi Hirano

Toshihiro Kumabe

Nobusada Shinoura

Naoya Hashimoto

Tomokazu Aoki

Akio Asai

Tatsuya Abe

Atsuo Yoshino

Yoshiki Arakawa

Kenichiro Asano

Koji Yoshimoto

Soichiro Shibui

机构：

[1] Nagoya University Graduate School of Medicine,Department of Neurosurgery

[2] National Cancer Center Hospital,JCOG (Japan Clinical Oncology Group) Data Center/Operations Office

[3] Cancer Institute Hospital,Radiation Oncology Department

[4] Saitama Medical University International Medical Center,Department of Neuro

[5] National Cancer Center Hospital,Oncology/Neurosurgery

[6] Tokyo Women’s Medical University,Department of Neurosurgery and Neuro

[7] Nakamura Memorial Hospital,Oncology

[8] Iwate Medical University,Department of Neurosurgery

[9] Kumamoto University Graduate School of Medicine,Department of Neurosurgery

[10] Yamagata University Graduate School of Medicine,Department of Neurosurgery

[11] Kyorin University Faculty of Medicine,Department of Neurosurgery

[12] Shizuoka Cancer Center,Department of Neurosurgery

[13] Hiroshima University,Department of Neurosurgery

[14] Graduate School of Biomedical and Health Sciences,Department of Neurosurgery

[15] Hiroshima University Hospital,Department of Neurosurgery

[16] Ehime University Graduate School of Medicine,Department of Clinical Oncology & Neuro

[17] Chiba University Graduate School of Medicine,oncology Program

[18] Kurume University Graduate School of Medicine,Department of Neurosurgery

[19] Hokkaido University Graduate School of Medicine,Department of Neurosurgery

[20] University of Tsukuba,Department of Neurosurgery

[21] Keio University School of Medicine,Department of Neurosurgery

[22] The University of Tokyo Hospital,Department of Neurosurgery, Faculty of Medicine

[23] Nagasaki University Graduate School of Medicine,Department of Neurosurgery

[24] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Neurosurgery

[25] Tohoku University Graduate School of Medicine,Department of Neurosurgery

[26] Kitasato University School of Medicine,Department of Neurosurgery

[27] Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital,Department of Neurosurgery

[28] Osaka University Graduate School of Medicine,Department of Neurosurgery

[29] Kitano Hospital,Department of Neurosurgery

[30] Kansai Medical University,Department of Neurosurgery

[31] Oita University Faculty of Medicine,Department of Neurosurgery

[32] Nihon University Graduate School of Medicine,Department of Neurosurgery

[33] Kyoto University Graduate School of Medicine,Department of Neurosurgery

[34] Hirosaki University Graduate School of Medicine,Department of Neurological Surgery

[35] Kyushu University,Department of Neurosurgery

来源：

Journal of Neuro-Oncology | 2018年 / 138卷

关键词：

Glioblastoma; Interferon-beta; Temozolomide; MGMT; RCT;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 636

页数：9

共 50 条

[1] JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
Wakabayashi, Toshihiko
Natsume, Atsushi
Mizusawa, Junki
Katayama, Hiroshi
Fukuda, Haruhiko
Sumi, Minako
Nishikawa, Ryo
Narita, Yoshitaka
Muragaki, Yoshihiro
Maruyama, Takashi
Ito, Tamio
Beppu, Takaaki
Nakamura, Hideo
Kayama, Takamasa
Sato, Shinya
Nagane, Motoo
Mishima, Kazuhiko
Nakasu, Yoko
Kurisu, Kaoru
Yamasaki, Fumiyuki
Sugiyama, Kazuhiko
Onishi, Takanori
Iwadate, Yasuo
Terasaki, Mizuhiko
Kobayashi, Hiroyuki
Matsumura, Akira
Ishikawa, Eiichi
Sasaki, Hikaru
Mukasa, Akitake
Matsuo, Takayuki
Hirano, Hirofumi
Kumabe, Toshihiro
Shinoura, Nobusada
Hashimoto, Naoya
Aoki, Tomokazu
Asai, Akio
Abe, Tatsuya
Yoshino, Atsuo
Arakawa, Yoshiki
Asano, Kenichiro
Yoshimoto, Koji
Shibui, Soichiro
JOURNAL OF NEURO-ONCOLOGY, 2018, 138 (03) : 627 - 636
[2] JCOG0911 INTEGRA TRIAL: A RANDOMIZED SCREENING PHASE II TRIAL OF CHEMORADIOTHERAPY WITH INTERFERONβ PLUS TEMOZOLOMIDE VERSUS CHEMORADIOTHERAPY WITH TEMOZOLOMIDE ALONE FOR NEWLY-DIAGNOSED GLIOBLASTOMA
Wakabayashi, Toshihiko
Natsume, Atsushi
Mizusawa, Junki
Katayama, Hiroshi
Fukuda, Haruhiko
Shibui, Soichiro
NEURO-ONCOLOGY, 2014, 16
[3] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Ciesielski, Michael J.
Reardon, David A.
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Figel, Sheila
Hutson, Alan
Groman, Adrienne
Withers, Henry
Liu, Song
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Khosla, Atulya
Casucci, Danielle
Mechtler, Laszlo
Fenstermaker, Robert
NEURO-ONCOLOGY, 2022, 24 : 66 - 66
[4] NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA
Sim, Hao-Wen
Lwin, Zarnie
Barnes, Elizabeth
McDonald, Kerrie
Yip, Sonia
Verhaak, Roel
Heimberger, Amy
Hall, Merryn
Wong, Matthew
Jennens, Ross
Ashley, David
Rosenthal, Mark
Hovey, Elizabeth
Ellingson, Benjamin
Tognela, Annette
Gan, Hui
Back, Michael
Koh, Eng-Siew
Long, Anne
Cuff, Katharine
Begbie, Stephen
Gedye, Craig
Mislang, Anna
Le, Hien
Johnson, Margaret
Kong, Benjamin
Simes, John
Khasraw, Mustafa
NEURO-ONCOLOGY, 2022, 24 : 65 - 65
[5] NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma
Sim, Hao-Wen
Wachsmuth, Luke
Barnes, Elizabeth H.
Yip, Sonia
Koh, Eng-Siew
Hall, Merryn
Jennens, Ross
Ashley, David M.
Verhaak, Roel G.
Heimberger, Amy B.
Rosenthal, Mark A.
Hovey, Elizabeth J.
Ellingson, Benjamin M.
Tognela, Annette
Gan, Hui K.
Wheeler, Helen
Back, Michael
Mcdonald, Kerrie L.
Long, Anne
Cuff, Katharine
Begbie, Stephen
Gedye, Craig
Mislang, Anna
Le, Hien
Johnson, Margaret O.
Kong, Benjamin Y.
Simes, John R.
Lwin, Zarnie
Khasraw, Mustafa
NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
[6] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
Athanassiou, H
Synodinou, M
Maragoudakis, E
Paraskevaidis, M
Verigos, C
Misailidou, D
Antonadou, D
Saris, G
Beroukas, K
Karageorgis, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2372 - 2377
[7] RANDOMIZED PHASE II TRIAL OF TUMOR TREATING FIELDS PLUS RADIATION THERAPY PLUS TEMOZOLOMIDE COMPARED TO RADIATION THERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Limon, D.
Bokstein, F.
Blumenthal, D.
Ben Harush, C.
Ram, Z.
Grossman, R.
NEURO-ONCOLOGY, 2019, 21 : 86 - 86
[8] Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma
Wen, PY
Gigas, DC
MacDonald, L
Batchelor, TT
Schiff, D
Xu, R
Ramakrishna, N
Weaver, S
Kracher, J
Bradshaw, J
Levy, B
Bailey, E
Kesari, S
Maher, EA
Henson, J
Black, PM
NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
[9] Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone
Atsushi Natsume
Kosuke Aoki
Fumiharu Ohka
Sachi Maeda
Masaki Hirano
Alimu Adilijiang
Kazuya Motomura
Minako Sumi
Ryo Nishikawa
Yoshitaka Narita
Yoshihiro Muragaki
Takashi Maruyama
Tamio Ito
Takaaki Beppu
Hideo Nakamura
Takamasa Kayama
Shinya Sato
Motoo Nagane
Kazuhiko Mishima
Yoko Nakasu
Kaoru Kurisu
Fumiyuki Yamasaki
Kazuhiko Sugiyama
Takanori Onishi
Yasuo Iwadate
Mizuhiko Terasaki
Hiroyuki Kobayashi
Akira Matsumura
Eiichi Ishikawa
Hikaru Sasaki
Akitake Mukasa
Takayuki Matsuo
Hirofumi Hirano
Toshihiro Kumabe
Nobusada Shinoura
Naoya Hashimoto
Tomokazu Aoki
Akio Asai
Tatsuya Abe
Atsuo Yoshino
Yoshiki Arakawa
Kenichiro Asano
Koji Yoshimoto
Soichiro Shibui
Yusuke Okuno
Toshihiko Wakabayashi
Journal of Neuro-Oncology, 2020, 148 : 17 - 27
[10] Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone
Natsume, Atsushi
Aoki, Kosuke
Ohka, Fumiharu
Maeda, Sachi
Hirano, Masaki
Adilijiang, Alimu
Motomura, Kazuya
Sumi, Minako
Nishikawa, Ryo
Narita, Yoshitaka
Muragaki, Yoshihiro
Maruyama, Takashi
Ito, Tamio
Beppu, Takaaki
Nakamura, Hideo
Kayama, Takamasa
Sato, Shinya
Nagane, Motoo
Mishima, Kazuhiko
Nakasu, Yoko
Kurisu, Kaoru
Yamasaki, Fumiyuki
Sugiyama, Kazuhiko
Onishi, Takanori
Iwadate, Yasuo
Terasaki, Mizuhiko
Kobayashi, Hiroyuki
Matsumura, Akira
Ishikawa, Eiichi
Sasaki, Hikaru
Mukasa, Akitake
Matsuo, Takayuki
Hirano, Hirofumi
Kumabe, Toshihiro
Shinoura, Nobusada
Hashimoto, Naoya
Aoki, Tomokazu
Asai, Akio
Abe, Tatsuya
Yoshino, Atsuo
Arakawa, Yoshiki
Asano, Kenichiro
Yoshimoto, Koji
Shibui, Soichiro
Okuno, Yusuke
Wakabayashi, Toshihiko
JOURNAL OF NEURO-ONCOLOGY, 2020, 148 (01) : 17 - 27

← 1 2 3 4 5 →